<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415350</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-2006-MCA1</org_study_id>
    <secondary_id>BAT-2006</secondary_id>
    <nct_id>NCT00415350</nct_id>
  </id_info>
  <brief_title>Bronchiectasis and Long Term Azithromycin Treatment</brief_title>
  <acronym>BAT</acronym>
  <official_title>Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. SUMMARY

      Rationale: Patients with bronchiectasis often experience lower respiratory tract infections
      with progression of symptoms and decline in quality of life. Macrolides, as has been shown in
      panbronchiolitis and cystic fibrosis, may break or weaken the link between infection and
      inflammation resulting in an improvement of symptoms. Also the number of exacerbations may
      lowered.

      Objective: A reduction in number of infective exacerbations and improvement in lung function
      by AZT treatment are the primary objectives. Secondary objectives that will be evaluated are:
      symptoms score, quality of life, inflammatory parameters, bacterial colonisation, and adverse
      events.

      Study design: Randomised double blind multicenter study in the Netherlands. Patients will be
      stratified for colonisation with P.aeruginosa.

      Study population: Patients with bronchiectasis demonstrated by high-resolution computed
      tomography (HR-CT) scan or bronchography.

      Intervention: Patients receive Azithromycin 250mg(p.o.) once daily or placebo.

      Main study parameters/endpoints: Reduction in number exacerbations, defined as increase
      symptoms such as dyspnoea, coughing, and sputum production for which a course of prednisolone
      and/or antibiotic is needed. Change in lung function parameters (forced expiratory volume in
      1 second [FEV1], forced vital capacity [FVC]) measured by spirometry is the other primary
      endpoint.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: The risk of participating in this study is low. Laboratory, radiographic
      examinations, and pulmonary function tests are commonly used as diagnostic procedures during
      outpatients visits and during exacerbations. Adverse effects in maintenance treatment with
      AZT are usually mild and mainly gastrointestinal. Sometimes rash and abnormal liver function
      tests are observed. A better quality of life will probably be the beneficial effect of long
      term treatment with AZT. This will be achieved by a reduction in respiratory and
      non-respiratory symptoms and number of exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does prolonged antibiotic treatment with AZM reduce the number of bacterial exacerbations in patients with bronchiectasis?</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Does treatment with AZM increase lung function parameters (Δ FEV1, Δ FVC )?</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is there any improvement in symptom score during treatment with AZM?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>What is the effect of AZM on bacterial colonisation?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does treatment with AZM reduce inflammatory parameters?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does treatment with AZM change the quality of life?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is there any differences in adverse events between AZM and placebo treatment?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Azithromycin treatment 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin Tablet 250 mg daily</description>
    <arm_group_label>Azithromycin treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet 1 daily</description>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 ≥ years

          -  Bronchiectasis diagnosed by plain bronchography or high resolution computer
             tomography.

          -  Minimal 3 lower respiratory tract infections (LRTI) treated with oral/intravenous (IV)
             antibiotics in the year preceding the study inclusion.

          -  The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of
             sputum.

          -  At least one positive sputum culture in the preceding year.

          -  Informed consent

        Exclusion Criteria:

          -  Previous ( ≥ 4 weeks) prolonged macrolide therapy.

          -  Pregnant or lactating women.

          -  Allergy to macrolides.

          -  Intolerance to macrolides.

          -  Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more
             times the upper limit of normal).

          -  Use of antibiotics within 14 days of screening.

          -  Use of oral or IV corticosteroids (≥ 30 mg prednisolone/daily) within 30 days of
             screening.

          -  Other research medication started 2 months prior to inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W.G. Boersma, MD,PHD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Center Alkmaar, dep. Pulmomary Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkmaar Medical Center</name>
      <address>
        <city>Alkmaar</city>
        <state>N-H</state>
        <zip>1800AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.C. Dekkerswald</name>
      <address>
        <city>Groesbeek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Ziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viecuri MC</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>W.G. Boersma</name_title>
    <organization>Alkmaar Medical Center</organization>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Macrolide</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Lung function</keyword>
  <keyword>Sputum</keyword>
  <keyword>Bacterial colonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

